Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2015

Open Access 01-12-2015 | Research

Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Authors: Wai Tong Chien, Jolene HC Mui, Eric FC Cheung, Richard Gray

Published in: Trials | Issue 1/2015

Login to get access

Abstract

Background

Non-adherence to antipsychotic medication is commonly found in schizophrenia and other psychotic disorders, thus forming a major obstacle to long-term maintenance treatment and contributing to high relapse rates. With limited evidence on the success of interventions in enhancing medication adherence, this controlled trial was designed to test and evaluate the effectiveness of an adherence therapy (AT) for outpatients with schizophrenia spectrum disorders, based on a motivational interviewing approach over a six-month follow-up period.

Methods

A single-blind, randomized controlled trial with a repeated-measures, two parallel groups design was conducted in a random sample of 114 participants with schizophrenia spectrum disorders in one community psychiatric nursing service. After pre-test, the participants were randomly assigned to either an eight-session course of AT plus usual care or usual psychiatric care (n = 57 per group). The main outcomes, including medication adherence, symptom severity, insight into treatment, hospitalization rate, and functioning, were measured at baseline and immediately and six months post-intervention.

Results

A total of 110 participants completed this trial and thus the attrition rate was 3.5 %. Results of repeated-measures analysis of variance followed by Helmert’s contrasts test indicated that the AT participants reported significantly greater improvements in their insight into illness and/or treatment, psychosocial functioning, symptom severity, number of re-hospitalizations, and medication adherence (F = 5.01 to 7.45, P = 0.007 to 0.030) over six months follow-up, when compared with usual care.

Conclusions

Motivational interviewing-based AT for people with schizophrenia can be effective to reduce symptom severity and re-hospitalizations, and improve medication adherence, functioning, and insight into illness and/or treatment over a medium term (six months) period of follow-up. Further study on the effects of AT in people with psychotic disorders in terms of diverse sociodemographic and illness characteristics, and a longer term (for example, over 12 months) follow-up period is recommended.

Trial registration

The trial was registered at Clinicaltrials.gov (identifier: NCT01780116) on 6 July 2014.
Literature
1.
Cheng L-Y, Chan S. Psychoeducation program for Chinese family carers of members with schizophrenia. West J Nurs Res. 2005;27:583–99.CrossRefPubMed
2.
Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance or compliance. Acta Psychiatr Scand. 2005;111:29–34.CrossRef
3.
McIntosh AM, Conlon L, Lawrie SM, Stanfield AC. Compliance therapy for schizophrenia. Cochrane Database Syst Rev. 2006;3, CD003442.PubMed
4.
Jaeger S, Pfiffner C, Weiser P, Kilian R, Becker T, Längle G, et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res. 2012;200:83–8.CrossRefPubMed
5.
Gray R, Wykes T, Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs. 2002;9:277–84.CrossRefPubMed
6.
Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraishi C, Yamauchi K, et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006;141:61–9.CrossRefPubMed
7.
Hui CL, Chen EY, Kan C, Yip K, Law C, Chiu CP. Antipsychotic adherence among out-patients with schizophrenia in Hong Kong. Keio J Med. 2006;55:9–14.CrossRefPubMed
8.
Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998;172:413–9.CrossRefPubMed
9.
Chien WT, Yip ALK. Current approaches to treatments for schizophrenia spectrum disorders, Part I: an overview and medical treatments. Neuropsychiatr Dis Treat. 2013;9:1311–32.CrossRefPubMedPubMedCentral
10.
Maayan N, Quraishi SN, David A, Jayaswai A, Eisenbruch M, Rathbone J, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;2, CD000307.PubMed
11.
Gray R, White J, Schultz M, Abderhalden C. Enhancing medication adherence in people with schizophrenia: an international programme of research. Int J Ment Health Nurs. 2010;19:36–44.CrossRefPubMed
12.
Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophr Res. 2013;146:59–63.CrossRefPubMed
13.
Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010;197:448–55.CrossRefPubMed
14.
Robinson DG. Medication adherence and relapse in recent-onset psychosis. Am J Psychiatry. 2011;168:240–2.CrossRefPubMed
15.
National Institute of Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management of schizophrenia. NICE guidelines CG178. London, UK: NICE; 2014.
16.
Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia: European multicentre randomized controlled trial. Br J Psychiatry. 2006;189:508–14.CrossRefPubMed
17.
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:698–702.CrossRef
18.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 5th ed. Washington, DC: APA; 2000.
19.
Chien WT, Chan SW, Thompson RD. Effects of mutual support group for Chinese families of people with schizophrenia: 18-month follow-up. Br J Psychiatry. 2006;189:41–9.CrossRefPubMed
20.
Cunningham JB, McCrum-Gardner E. Power, effect and sample size using GPower: practical issues for researchers and members of research ethics committees. Evid Based Midwifery. 2007;5:132–6.
21.
Chien WT, Leung SF. A controlled trial of a needs-based, nurse-led psycho-education program for Chinese patients with first-onset mental disorders: 6-month follow-up. Int J Nurs Practice. 2013;19:s3–s13.CrossRef
22.
Chien WT, Yeung FKK, Chan AHL. Perceived stigma of patients with severe mental illness in Hong Kong: relationships with patients’ psychosocial conditions and attitudes for family caregivers and health professionals. Adm Policy Ment Health. 2014;41:237–51.CrossRefPubMed
23.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.CrossRefPubMed
24.
Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The positive and negative syndrome scale and brief psychiatric rating scale: reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992;180:723–8.CrossRefPubMed
25.
Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286–90.CrossRefPubMed
26.
McEvoy JP, Apperson LG, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, et al. Insight in schizophrenia: its relation to acute psychopathology. J Nerv Ment Dis. 1989;177:43–7.CrossRefPubMed
27.
Chien WT, Thompson DR. Effects of a mindfulness-based psycho-education programme for Chinese patients with schizophrenia: two-year follow-up. Br J Psychiatry. 2014;205:52–9.CrossRefPubMed
28.
Schneider LC, Struening EL. SLOF: a behavioural rating scale for assessing the mentally ill. Soc Work Res Abstr. 1983;19:9–21.CrossRefPubMed
29.
Chien WT, Chan CWS. One-year follow-up of a multiple-family-group intervention for Chinese families of patients with schizophrenia. Psychiatr Serv. 2004;55:1276–84.CrossRefPubMed
30.
Chien WT, Chan S. Further validation of the Chinese version of the level of expressed emotion scale for research and clinical use. Int J Nurs Stud. 2010;47:190–204.CrossRefPubMed
31.
Tabachnick BG, Fidell LS. Using multivariate analysis. 4th ed. Old Tappan, New Jersey: Allyn & Bacon; 2001.
32.
Stevens J. Applied multivariate statistics for the social sciences. 4th ed. Mahwah, New Jersey: Psychology Press; 2002.
33.
O’Donnell M, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ. 2003;327:834.CrossRefPubMedPubMedCentral
34.
Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs. 2007;16:1302–12.CrossRefPubMed
35.
Levensky ER, Forcehimes A, O’Donohue WT, Beitz K. Motivational interviewing: an evidence-based approach to counseling helps patients follow treatment recommendations. Am J Nurs. 2007;107:50–8.CrossRefPubMed
36.
Haynes RB, McDonald H, Grag AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2, CD000011.PubMed
37.
Yang H. Strategic analysis of clinical trial outsourcing to China [dissertation]. British Columbia: Simon Fraser University; 2008.
38.
Hegedüs A, Kozel B. Does adherence therapy improve medication adherence among patients with schizophrenia? A systematic review. Int J Ment Health Nurs. 2014;23:490–7.CrossRefPubMed
39.
Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102:203–10.CrossRefPubMed
40.
Dawn V, Weiden P, Sajatovic M, Scott J, Carpenter D, Ross R, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from expert consensus guidelines. J Psychiatr Practice. 2010;16:306–24.CrossRef
Metadata
Title
Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial
Authors
Wai Tong Chien
Jolene HC Mui
Eric FC Cheung
Richard Gray
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Trials / Issue 1/2015
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-015-0785-z

Other articles of this Issue 1/2015

Trials 1/2015 Go to the issue

Study protocol

The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial

Study protocol

Rumination-focused cognitive behaviour therapy vs. cognitive behaviour therapy for depression: study protocol for a randomised controlled superiority trial

Study protocol

Cognitive behavioral therapy for adults with attention-deficit hyperactivity disorder: study protocol for a randomized controlled trial

Study protocol

Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial

Study protocol

The effectiveness of Tai Chi for patients with Parkinson’s disease: study protocol for a randomized controlled trial

Research

Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center